My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

39.84 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

1 Stock Under $50 with Exciting Potential and 2 to Ignore

March 04, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

February 27, 2025

From Royalty Pharma plc

Via GlobeNewswire

Peering Into Royalty Pharma's Recent Short Interest ↗

February 24, 2025

Via Benzinga

Insights Ahead: Royalty Pharma's Quarterly Earnings ↗

November 05, 2024

Via Benzinga

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma ↗

February 12, 2025

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.

Via Benzinga

Royalty Pharma Announces R&D Funding Collaboration With Biogen

February 12, 2025

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates

February 11, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share was...

Via StockStory

Royalty Pharma Reports Q4 and Full Year 2024 Results

February 11, 2025

From Royalty Pharma plc

Via GlobeNewswire

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday? ↗

February 11, 2025

U.S.

Via Benzinga

Royalty Pharma Earnings: What To Look For From RPRX

February 10, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for.

Via StockStory

Earnings Scheduled For February 11, 2025 ↗

February 11, 2025

Via Benzinga

Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

January 29, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

January 28, 2025

From Royalty Pharma plc

Via GlobeNewswire

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? ↗

January 12, 2025

Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United...

Via Benzinga

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗

January 10, 2025

Via Benzinga

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

January 10, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

January 10, 2025

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Dividend Increase

January 09, 2025

From Royalty Pharma plc

Via GlobeNewswire

Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock ↗

December 20, 2024

Jim Cramer likes Walmart (WMT). Walmart provides body cameras to employees in a pilot program. Cramer says Royalty Pharma (RPRX) is a disappointing stock.

Via Benzinga

3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer ↗

December 13, 2024

Via The Motley Fool

2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips ↗

December 04, 2024

Via The Motley Fool

3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer ↗

December 03, 2024

Via The Motley Fool

Royalty Pharma to Present at Upcoming Investor Conferences

November 27, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

November 14, 2024

From Royalty Pharma plc

Via GlobeNewswire

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade ↗

November 14, 2024

Via The Motley Fool

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

November 07, 2024

From Royalty Pharma plc

Via GlobeNewswire

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗

November 06, 2024

Via Benzinga

Royalty Pharma Reports Third Quarter 2024 Results

November 06, 2024

From Royalty Pharma plc

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.